NanoPac made available for patients who Don't qualify for trials
NCT ID NCT03756311
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers expanded access to NanoPac, a cancer treatment, for people with advanced pancreatic, prostate, or lung cancer who cannot join ongoing clinical trials. The goal is to provide the drug to those who have no other options. However, the program is no longer available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Locally advanced pancreatic carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive missile aims at prostate cancer that spread
- Surgeons could freeze lung tumors from miles away using 5G robots
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can AI make lung cancer scans easier to read?
- Can a new PET tracer spot hidden prostate cancer spread?